Separate names with a comma.
LSD Just Passed Its Biggest Trial Yet for Anxiety https://gizmodo.com/lsd-just-passed-its-biggest-trial-yet-for-anxiety-2000797652 It's the...
After today’s positive Phase 3 VOYAGE results in GAD, I think the risk profile around DT120 has changed substantially. We now have two successful...
Definium says LSD-based pill reduces anxiety in late-stage study...
Psychedelics developer Definium scores more positive data for LSD pill...
Fireside chat at Canaccord Genuity's 46th Annual Growth Conference...
DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial...
Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readout...
Today's dip might be the last low price here. Going up.... very very soon.
Institute for Integrative Therapies Selected as Clinical Trial Site for COMPASS Pathways’ Psilocybin Treatment for PTSD...
All eyes on psychedelic drugmakers as Definium, Compass near major catalysts...
Psychedelics on the cusp of market breakthrough as clinical, policy support grow...
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights...
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin...
COMPASS Pathways investor presentation August 2026 https://s204.q4cdn.com/927483861/files/doc_presentation/2026/07/FINAL_CMPS_IR-Deck_AUG2026.pdf
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights August 5, 2026...
Three potential takeover targets in psychedelics https://www.pharmavoice.com/news/three-potential-takeover-targets-psychedelics-drug/826887/
Unlocking the Next Step in Compass’ Journey https://www.linkedin.com/pulse/unlocking-next-step-compass-journey-kabir-nath-d2zxc/
